Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | XIAP | P98170 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133811 | 0.89 | NPC1 (0.40) | TP53XIAPKDM4EALDH1A1HSD17B10 | |
| SCHEMBL6133161 | 0.87 | L3MBTL1 (0.47) | ALDH1A1HSD17B10POLB | |
| SCHEMBL6134311 | 0.87 | HPGD (0.41) | TP53KDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL6133425 | 0.87 | RET (0.41) | TP53XIAPKDM4EALDH1A1MAPT | |
| SCHEMBL6133465 | 0.86 | HSD17B10 (0.39) | TP53XIAPKDM4EALDH1A1HSD17B10 | |
| SCHEMBL6134642 | 0.86 | TP53 (0.41) | TP53XIAPKDM4EALDH1A1HSD17B10 | |
| SCHEMBL6135410 | 0.86 | RAB9A (0.44) | KDM4EALDH1A1POLBCYP1A2CYP2C9 | |
| SCHEMBL6133793 | 0.86 | HSD17B10 (0.46) | TP53KDM4EHSD17B10HTT | |
| SCHEMBL6134990 | 0.86 | MAPT (0.42) | ALDH1A1HSD17B10MAPTPOLBCYP1A2 | |
| SCHEMBL6133813 | 0.85 | ALOX15 (0.46) | TP53XIAPKDM4EPTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1441732-A2 | THIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003039451-A2 | THIAZOLE PYRIDAZINONES AS ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | MC2R, CYP2C9, OXTR | TP53 4124/4885XIAP 4881/4885KDM4E 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.